What’s in Ozzi: ingredients, amounts and research
Built for the moment snack cravings hit. Explore the six actives in our drink, the five in our capsules, and the research that informed their selection.
Last reviewed September 9, 2026
The drink formula, per stick
| Ingredient | Amount and form |
|---|---|
| Allulose | 8 g allSWEET allulose |
| Konjac | 500 mg konjac glucomannan |
| Butyrate | 500 mg BIOMEnd L-lysine butyrate |
| African mango | 150 mg African mango seed extract |
| Ursolic acid | 10 mg ursolic acid, supplied through Metabolex chromium polyursolate |
| Chromium | 300 mcg elemental chromium, supplied through Metabolex chromium polyursolate |
Capsules contain five actives: konjac glucomannan, L-lysine butyrate, African mango, ursolic acid and chromium. They do not contain allulose. The 3-capsule label lists 300 mcg chromium and a 1.15 g proprietary blend; individual amounts within that blend are not disclosed.
Chromium and ursolic acid are two actives supplied together through Metabolex chromium polyursolate. Their evidence is explained separately below.
Allulose
8 g allSWEET allulose
Allulose gives the drink its sweet taste and contributes to the formula’s blood-sugar and gut-hormone rationale. Human trials have found lower post-meal glucose responses at amounts close to the 8 g in one stick.
What the evidence shows
The 8 g amount was informed by glucose studies, including 7.5–10 g with sucrose and 8.5 g with meals. Separate human experiments found increased GLP-1 with 10 g alongside a meal and 25 g delivered into the stomach. Those findings support the ingredient rationale; they do not establish the GLP-1 or snacking effect of an 8 g Ozzi serving.
How the ingredient is being studied
Allulose has increased gut hormones in human experiments, but a simple “sweet receptors in the stomach” explanation is not established. In the 25 g experiment, blocking the sweet-taste receptor with lactisole did not prevent the hormone response.
Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study.
30 adults without diabetes; randomized crossover; 2.5, 5, 7.5 or 10 g with 50 g sucrose.
Allulose reduced the early post-drink glucose response in a dose-dependent pattern, with significant reductions at 7.5 and 10 g. The 10 g dose also reduced glucose and insulin excursions.
Read the original publicationA Pilot Study on the Efficacy of a Diabetic Diet Containing the Rare Sugar D-Allulose in Patients with Type 2 Diabetes Mellitus: A Prospective, Randomized, Single-Blind, Crossover Study.
Randomized crossover pilot in type 2 diabetes; 8.5 g allulose per meal; continuous glucose monitoring.
A diabetic diet containing 8.5 g allulose per meal reduced post-meal glucose peaks compared with the standard diabetic diet. This supplies another near-serving-dose example of human glucose research.
Read the original publicationDifferential Modulation of Postprandial Glycemic, Incretin, and Satiety Responses by Low-Digestible Carbohydrates in Humans: An Exploratory Investigation.
Two exploratory investigations, 10 participants each; 25 g carbohydrate testing and a separate 10 g allulose plus meal experiment.
In the meal experiment, 10 g allulose lowered post-meal glucose and insulin responses and increased circulating active GLP-1 compared with the meal alone. A statistically significant satiety improvement was reported for resistant maltodextrin, not allulose.
Read the original publicationThe Role of D-allulose and Erythritol on the Activity of the Gut Sweet Taste Receptor and Gastrointestinal Satiation Hormone Release in Humans: A Randomized, Controlled Trial.
18 healthy adults; randomized double-blind crossover; 25 g allulose delivered into the stomach, with or without lactisole.
Allulose increased GLP-1, PYY and CCK relative to water. Blocking the intestinal sweet-taste receptor with lactisole did not stop these responses, indicating that this receptor was not the mediator under the tested conditions.
Read the original publicationGlycemic and cardiometabolic effects of rare sugars allulose and tagatose: a systematic review and meta-analysis of controlled human intervention trials.
2026 review; 20 trials total, of which 12 studied allulose and eight tagatose; search through April 2025.
Pooled allulose results supported lower post-meal glucose and insulin responses with moderate certainty. The review did not find significant pooled improvements in fasting glucose, HbA1c, lipids or body composition.
Read the original publicationKonjac
500 mg konjac glucomannan
Konjac glucomannan is a soluble fiber that forms a viscous mixture with water. This physical property is why it is included in a formula designed around fullness.
What the evidence shows
Human glucomannan studies report mixed results for weight and metabolic outcomes. Many supplement trials used several grams per day, above the 500 mg in an Ozzi stick; laboratory viscosity findings explain a property of the fiber rather than proving appetite reduction at this serving.
How the ingredient is being studied
Viscosity can influence the movement and mixing of food through the digestive tract. The gastric-emptying study below used a laboratory digestion model, not people drinking Ozzi. Always follow the product’s water directions.
In vitro gastric emptying characteristics of konjac glucomannan with different viscosity and its effects on appetite regulation.
22 healthy adults; randomized single-blind crossover breakfasts with different viscosities; separate simulated gastric-emptying experiments.
Higher-viscosity breakfasts improved subjective hunger, fullness and desire-to-eat ratings and altered appetite-related hormone responses. Subsequent food intake changed only slightly.
Read the original publicationEffect of glucomannan on obese patients: a clinical study.
20 adults with obesity; double-blind eight-week study; 1 g glucomannan with water before each of three meals daily.
The study reported weight loss and lower cholesterol measures in the glucomannan group without requested changes to eating or exercise. It is an early positive clinical study of a pre-meal fiber regimen.
Read the original publicationSafety and efficacy of glucomannan for weight loss in overweight and moderately obese adults.
53 overweight or moderately obese adults; randomized trial; 1.33 g before each of three meals, with water, for eight weeks.
Glucomannan did not outperform placebo for weight, body composition, hunger, fullness, glucose or lipids. The investigators found the regimen generally tolerable.
Read the original publicationThe effect of Glucomannan on fasting and postprandial blood glucose in adults: a systematic review and meta-analysis of randomized controlled trials.
Six adult randomized trials with 124 participants; glucose outcomes.
The review found a reduction in fasting glucose but no statistically significant pooled reduction in post-meal glucose. The fasting-glucose effect was clearer in the diabetes subgroup.
Read the original publicationButyrate
500 mg BIOMEnd L-lysine butyrate
Butyrate is a short-chain fatty acid involved in gut-cell energy and signaling. Ozzi uses L-lysine butyrate to supply this postbiotic directly.
What the evidence shows
Human sodium-butyrate trials have examined glucose regulation and other metabolic outcomes, with results that vary by population and formulation. A separate small human absorption study compared lysine butyrate with other delivery forms; it did not measure appetite or GLP-1.
How the ingredient is being studied
Cell and animal studies connect short-chain fatty-acid signaling with GLP-1 release. These explain a plausible gut pathway. The lysine-butyrate absorption study matched 786 mg of butyric acid across forms, which is not the same as 500 mg of the L-lysine butyrate compound in Ozzi.
A Pharmacokinetic Comparison of Three Butyrate Products
10 healthy men; randomized crossover; lysine butyrate, sodium butyrate and tributyrin, each providing 786 mg butyric acid.
Lysine and sodium butyrate produced greater systemic exposure and earlier peak concentrations than tributyrin. The mean lysine-butyrate peak occurred at the first post-dose sample, 20 minutes.
Read the original publicationEffect of Butyrate and Inulin Supplementation on Glycemic Status, Lipid Profile and Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial.
60 adults with type 2 diabetes; four groups; sodium butyrate, inulin, both or placebo for 45 days.
Sodium butyrate alone and the butyrate–inulin combination increased GLP-1 compared with placebo. Several other changes were confined to combination treatment or comparisons within a group.
Read the original publicationTargeting weight loss and blood glucose control with oral sodium butyrate in overweight/obese adults with and without type 2 diabetes: A proof-of-concept randomized controlled trial.
46 adults, including 23 with type 2 diabetes; 1,875 mg sodium butyrate daily or placebo, with the same reduced-energy diet for 12 weeks.
In participants without diabetes, butyrate produced greater weight loss than placebo; in those with diabetes, weight changes were similar but triglycerides and a continuous-glucose-monitoring measure improved. The 2026 results suggest that benefits can depend on metabolic status.
Read the original publicationShort-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2.
Primary intestinal cell cultures and mice lacking the SCFA receptors FFAR2 or FFAR3.
Short-chain fatty acids stimulated GLP-1 release, and receptor disruption reduced this response. The findings support a receptor-mediated link between intestinal fermentation products and hormone secretion.
Read the original publicationThe impact of butyrate on glycemic control in animals and humans: a comprehensive semi-systemic review.
2025 semi-systematic review of animal and human butyrate research.
The review describes strong mechanistic interest but uneven translation to humans because delivery, absorption, metabolism and baseline health differ. It calls for better human trials while recognizing multiple plausible metabolic pathways.
Read the original publicationAfrican mango
150 mg African mango seed extract
African mango (Irvingia gabonensis) seed extracts have been studied for body measurements, glucose and metabolic markers. This research informed its inclusion in Ozzi’s multi-ingredient formula.
What the evidence shows
Some small human trials report favorable changes in weight, waist size and metabolic markers. Reviews also identify substantial limitations in the evidence. Extract identity matters: a result for a named extract such as IGOB131 is not automatically a result for every African mango ingredient.
How the ingredient is being studied
Cell studies have explored adipocyte and leptin-related pathways. They provide mechanism context, while human trials and their quality determine how confidently an outcome can be predicted.
IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation.
102 overweight or obese adults; randomized double-blind study; IGOB131 extract 150 mg twice daily before meals for 10 weeks.
IGOB131 improved weight, waist and body-fat measures as well as several metabolic markers compared with placebo. This is an important positive study of a specific African-mango seed extract.
Read the original publicationThe effect of Irvingia gabonensis seeds on body weight and blood lipids of obese subjects in Cameroon.
40 adults with obesity; 28 active and 12 placebo; seed preparation 1.05 g three times daily for one month.
The active group lost more weight than placebo and showed favorable changes in blood lipids. The study supports early clinical interest in African-mango seed preparations.
Read the original publicationEffect of Irvingia gabonensis on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion.
24 adults with metabolic syndrome; 150 mg extract twice daily or placebo for 90 days.
The treated group showed improvements in waist and several glucose or lipid measures, and more participants met criteria for metabolic-syndrome remission than with placebo. Several numerical results in the abstract are within-group comparisons.
Read the original publicationEffects of Irvingia gabonensis Extract on Metabolism, Antioxidants, Adipocytokines, Telomere Length, and Aerobic Capacity in Overweight/Obese Individuals.
Overweight or obese adults; observation phase followed by randomized 300 mg extract daily or placebo for 12 weeks.
The extract increased vitamin C and adiponectin at selected time points but did not improve the broader metabolic, adiposity, inflammation or fitness outcomes versus placebo. This limits claims of consistent weight-loss efficacy.
Read the original publicationThe Effects of Irvingia gabonensis Seed Extract Supplementation on Anthropometric and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.
Five randomized trials; four rated high risk of bias and one low risk.
Pooled weight and lipid results favored African-mango extracts, but trial quality weakened confidence. The one low-risk trial did not show statistically significant outcome differences.
Read the original publicationUrsolic acid
10 mg ursolic acid, supplied through Metabolex chromium polyursolate
Ursolic acid is a plant compound studied for cellular energy pathways. It is one of two actives delivered together in Ozzi through Metabolex chromium polyursolate.
What the evidence shows
Animal and cell studies provide the clearest mechanism evidence. Human studies have used different formulations and generally higher doses; a 2024 meta-analysis did not find consistent overall cardiometabolic benefits. These studies do not establish fat-loss or muscle benefits from Ozzi’s 10 mg serving.
How the ingredient is being studied
Research has explored AMPK and other pathways involved in energy use. Formulation can affect absorption, but published numerical absorption or dose-equivalence claims for Ozzi’s Metabolex form are not established by the studies in this library.
Effect of Ursolic Acid on Metabolic Syndrome, Insulin Sensitivity, and Inflammation.
24 adults with untreated metabolic syndrome; 150 mg ursolic acid daily or placebo for 12 weeks.
The ursolic-acid group showed improvements in weight, waist, fasting glucose and insulin sensitivity. This small trial provides a positive human signal for metabolic research.
Read the original publicationUrsolic acid has no additional effect on muscle strength and mass in active men undergoing a high-protein diet and resistance training: A double-blind and placebo-controlled trial.
22 active men; 400 mg/day ursolic acid or placebo with resistance training and a high-protein diet for eight weeks.
Both groups gained strength and muscle during training, but ursolic acid provided no additional benefit. This challenges a broad claim that ursolic acid reliably builds or preserves muscle in humans.
Read the original publicationUrsolic acid increases skeletal muscle and brown fat and decreases diet-induced obesity, glucose intolerance and fatty liver disease.
High-fat-fed mice receiving a diet with ursolic acid.
Ursolic acid increased muscle Akt signaling, muscle and brown-fat measures, and energy expenditure while improving obesity-related outcomes. The work provides a biological rationale for metabolic and muscle research.
Read the original publicationUrsolic acid increases energy expenditure through enhancing free fatty acid uptake and β-oxidation via an UCP3/AMPK-dependent pathway in skeletal muscle.
Diet-induced obese rats receiving 0.5% ursolic acid for six weeks, plus cell experiments.
Ursolic acid increased fatty-acid uptake and oxidation through an UCP3/AMPK-linked pathway. The animal experiments also showed lower weight and altered muscle lipid metabolism.
Read the original publicationThe effects of ursolic acid on cardiometabolic risk factors: a systematic review and meta-analysis.
Six articles; adult doses 50.94–450 mg/day; search through February 2023.
The meta-analysis did not find significant pooled improvements in body size, body composition, glucose, insulin, blood pressure or the reported lipid outcomes. Human cardiometabolic efficacy remains uncertain despite favorable mechanisms and some small trials.
Read the original publicationChromium
300 mcg elemental chromium, supplied through Metabolex chromium polyursolate
Chromium is a trace mineral involved in carbohydrate metabolism. Ozzi supplies it with ursolic acid through Metabolex chromium polyursolate, while explaining the two actives separately.
What the evidence shows
Human chromium studies include appetite, food intake and glucose outcomes, with positive and mixed results. A small appetite trial used 1,000 mcg/day of chromium picolinate; Ozzi supplies 300 mcg chromium in a different form. The trial informs the rationale, but does not directly test this formula.
How the ingredient is being studied
Chromium research examines insulin-related metabolism and appetite regulation. Differences in baseline health, dose and chromium form matter when interpreting the findings.
Effects of chromium picolinate on food intake and satiety.
42 overweight women reporting carbohydrate cravings; 1,000 mcg elemental chromium as picolinate daily versus placebo for eight weeks; 40 analyzed.
Chromium picolinate reduced measured food intake, hunger and fat cravings compared with placebo. The difference in weight change did not reach statistical significance.
Read the original publicationA double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving.
113 adults with atypical depression; 600 mcg elemental chromium as picolinate daily or placebo for eight weeks.
The main depression outcomes did not differ significantly between groups. Appetite-related symptoms and an exploratory subgroup with pronounced carbohydrate cravings showed favorable signals.
Read the original publicationChromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes.
Adults with type 2 diabetes on glipizide; 29 randomized to placebo or 1,000 mcg chromium as picolinate for six months.
Chromium improved insulin sensitivity and glucose control and attenuated weight gain compared with placebo. The effect occurred in a medication-treated diabetes population.
Read the original publicationA meta-analysis of the effect of chromium supplementation on anthropometric indices of subjects with overweight or obesity.
21 trials from 19 studies involving 1,316 overweight or obese participants.
Chromium was associated with small pooled reductions in weight, BMI and body-fat percentage; the average weight difference was about 0.75 kg. The authors questioned how clinically meaningful these changes were.
Read the original publicationChromium supplementation and type 2 diabetes mellitus: an extensive systematic review.
Review of randomized diabetes trials published from 2000 through January 2024; multiple chromium forms and doses.
Several trials reported improved glucose or lipid markers, while inconsistency in form, dose and study design limited confidence. The review called for better research to clarify benefits and risks.
Read the original publicationAllulose and digestive tolerance
Ozzi uses 8 g allulose per stick. Tolerance depends on the amount taken at once, total intake and the individual. Published research does not establish 25 g as a universal symptom threshold, or establish how often symptoms occur with an 8 g Ozzi serving. Some studies report mild, temporary digestive symptoms at lower amounts; the study details below show the actual dosing and design.
Gastrointestinal Tolerance of D-Allulose in Healthy and Young Adults. A Non-Randomized Controlled Trial.
29 young adults in a non-randomized dose-escalation experiment; single doses 0.1–0.5 g/kg and separate daily escalation.
Gastrointestinal symptoms became more prominent at higher doses, and the authors proposed 0.4 g/kg as a maximum single dose and 0.9 g/kg as a daily maximum for the studied setting. Symptoms could still occur below those proposed limits.
Read the original publicationD-Allulose as a Low-Calorie Sweetener: A 30-Day Randomized, Double-Blind Study on Gastrointestinal Tolerance and Systemic Safety to Support Its Application in Healthy Diets.
50 healthy Chinese adults randomized; 49 completed; 12 g twice daily or 18 g twice daily for 30 days; no zero-allulose control.
At 24 or 36 g daily, gastrointestinal symptoms were reported as generally mild and transient, most often early in use. The paper reports symptoms in 48% overall, with no significant difference between dose groups and measured laboratory changes remaining within clinical reference ranges.
Read the original publicationThe full label, including other ingredients
Chicory root inulin remains listed under Other Ingredients on the capsule label. It is not one of the five actives we promote. The label also lists hypromellose, silica and a rice extract blend (rice bran, rice hulls, gum arabic and sunflower oil).
Made for your snack-time routine
Mix one drink stick with 16–20 oz of cold water when snack cravings hit, including after dinner. For capsules, take 3 with at least 12 oz of water as an alternative to an unplanned snack; they can also be taken before a meal. Follow each product’s current label for frequency and dose spacing.
Customers tell us about quieter cravings and easier evenings. Those experiences are part of why we offer the 14-Day Ozzi Challenge. Ingredient studies help explain the formula’s rationale; customer reviews are not controlled trials of the finished product.